Galmed Pharmaceuticals Total Assets Over Time
| GLMD Stock | USD 2.86 0.01 0.35% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Galmed Pharmaceuticals Performance and Galmed Pharmaceuticals Correlation. Galmed |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Assets Analysis
Compare Galmed Pharmaceuticals and related stocks such as Evofem Biosciences, Affimed NV, and Abeona Therapeutics Total Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AFMD | 7.2 M | 7.2 M | 7.2 M | 6.5 M | 41.9 M | 79.3 M | 48.7 M | 43.2 M | 116.2 M | 112.4 M | 175.7 M | 225.1 M | 200.5 M | 97.2 M | 105.8 M |
| ABEO | 2.1 M | 3.8 M | 1.7 M | 613 K | 16.6 M | 80.1 M | 111.1 M | 178.8 M | 174.4 M | 223.4 M | 151.2 M | 79.6 M | 64.2 M | 64 M | 49.3 M |
| AKBA | 2.2 M | 2.2 M | 2.2 M | 34.7 M | 111 M | 142.9 M | 300.2 M | 364.2 M | 996.5 M | 771.2 M | 644.1 M | 525.5 M | 351.8 M | 241.7 M | 411.2 M |
| KOD | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 3.2 M | 92.2 M | 358.9 M | 1.1 B | 904.2 M | 666.6 M | 479.4 M | 492.8 M |
| MREO | 107.3 M | 107.3 M | 107.3 M | 107.3 M | 107.3 M | 107.3 M | 86.8 M | 96.3 M | 67.3 M | 86.4 M | 62.9 M | 126.4 M | 88.1 M | 66.5 M | 70.1 M |
| ADVM | 386 K | 386 K | 386 K | 1.1 M | 161.9 M | 264.3 M | 234.6 M | 201.9 M | 213.5 M | 222.7 M | 482.6 M | 439.7 M | 308.4 M | 173 M | 247.9 M |
| ADAP | 4 M | 4 M | 1.8 M | 55.5 M | 300.7 M | 300.7 M | 234.5 M | 281.1 M | 276.7 M | 181.5 M | 451.1 M | 469.5 M | 328.9 M | 282.6 M | 268.1 M |
| PIRS | 10.6 M | 10.6 M | 10.6 M | 7.3 M | 21.9 M | 34 M | 35.1 M | 103.9 M | 141.3 M | 141.1 M | 105 M | 153.6 M | 95.5 M | 38.7 M | 36.7 M |
| PDSB | 8.7 M | 8.7 M | 8.7 M | 8.7 M | 17 M | 134.1 M | 110.9 M | 92.6 M | 36.2 M | 14.5 M | 30.9 M | 67.2 M | 77 M | 59.4 M | 64.9 M |
| LPTX | 17.7 M | 17.7 M | 17.7 M | 20.7 M | 48.7 M | 28.1 M | 6.5 M | 29.1 M | 19.1 M | 7.4 M | 54.4 M | 117.9 M | 70.4 M | 72.8 M | 45.2 M |
| FBIO | 1.7 M | 23.4 M | 41 M | 100.6 M | 89.3 M | 118.6 M | 170.7 M | 245.9 M | 141 M | 226.4 M | 328.8 M | 396.5 M | 294.3 M | 167.5 M | 173.1 M |
| MBIO | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 63.5 M | 42.8 M | 73.4 M | 109.9 M | 125.2 M | 92.4 M | 17.7 M | 16.9 M |
| ACHL | 105.2 M | 105.2 M | 105.2 M | 105.2 M | 105.2 M | 105.2 M | 105.2 M | 105.2 M | 105.2 M | 105.2 M | 218.9 M | 317.1 M | 220.4 M | 161.5 M | 225.1 M |
| APTO | 7.7 M | 2.1 M | 648.2 K | 1 M | 28.5 M | 15.3 M | 8.6 M | 12 M | 16.9 M | 100.5 M | 126.3 M | 82.5 M | 51 M | 13 M | 12.3 M |
Galmed Pharmaceuticals and related stocks such as Evofem Biosciences, Affimed NV, and Abeona Therapeutics Total Assets description
Total assets refers to the total amount of Galmed Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Galmed Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.My Equities
My Current Equities and Potential Positions
| Galmed Pharmaceuticals | GLMD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Israel |
| Exchange | NASDAQ Exchange |
USD 2.86
Check out Galmed Pharmaceuticals Performance and Galmed Pharmaceuticals Correlation. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Galmed Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.